Shots:
- Antengene has licensed ATG-106, a preclinical CDH6×CD3 bispecific T-cell engager for solid tumors, to K2 Therapeutics & granted an option for exclusive rights to a second undisclosed bispecific TCE candidate, covering all global markets excl. Greater China
- As per the licensing deal, Antengene will receive $20M in upfront & near-term consideration, incl. cash & a minority equity stake in a K2’s subsidiary, plus ~$960.5M in development, regulatory, & sales milestones, with tiered royalties on future net sales.
- Upon exercise of the option, Antengene will receive ~$20M, incl. an option exercise fee, upfront, & a minority equity stake in the related asset company. It would also receive ~$960.5M in development, regulatory, & sales milestones, plus tiered royalties
Ref: PRnewswire | Image: Antengene & K2 Therapeutics | Press Release
Related News: Antengene and UCB Strike ~$1.18B Deal to Advance ATG-201 for B-Cell–Related Autoimmune Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
